Association between time to stent dysfunction and the anti-tumour effect of systemic chemotherapy following stent placement in patients with pancreaticobiliary cancers and malignant gastric outlet obstruction: a retrospective cohort study

Table 2 Cumulative incidence of stent dysfunction in each background

Factor	at 6-months, %	at 1-year, %	p-value^†
Primary disease			0.33
Pancreatic adenocarcinoma	21.6	31.7
Biliary tract cancers	13.9	13.9
Pancreatic neuroendocrine tumours	37.5	37.5
Disease status			0.92
Locally advanced	22.1	31.4
Metastatic	20.6	28.9
^*ECOG PS			0.37
0–1	19.3	27.7
2–3	24.6	33.6
Chemotherapy regimen			0.61
^¶Combo	23.0	28.4
^#Mono-	19.4	30.3
Indication of chemotherapy			0.74
First-line	21.6	28.3
Salvage-line	20.5	30.7
Response to chemotherapy^a			0.69
Partial response	9.5	20.1
Stable or progressive disease	20.1	30.3

^a According to the New response evaluation criteria in solid tumours, version 1.1
^*ECOG PS Eastern Cooperative Oncology Group performance status, ^¶Combo combination regimens such as FOLFIRINOX, gemcitabine plus nab-paclitaxel, gemcitabine plus cisplatin and gemcitabine plus S-1, ^#Mono monotherapy such as gemcitabine alone or S-1 alone
^† The Gray test

ISSN: 1471-2407